A Phase 4 interventional study of Entecavir in Hepatitis B Infection, sponsored by Bristol-Myers Squibb. Completed at 27 sites in 5 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-04-16.
Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.
Among the 37 studies testing entecavir in Hepatitis B, this one is the 15th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2006, is one of 20 in phase 4, and was the 5th registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:
Bangladesh Medical University · Sites in Bangladesh
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Taichung Veterans General Hospital · Sites in Taiwan
Ages 20+
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 6 · Phase 4 20
First in 2001; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 131 is close to the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 106 across the 36 interventional studies. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 37 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
12 studies in Hepatitis B by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 12 studies in Hepatitis B by Bristol-Myers Squibb, this one is the only one that started in 2006, is the only one in phase 4, and was the 5th registered.
Bristol-Myers Squibb’s Hepatitis B studies by the year they started, since 2001.
3 of the studies testing entecavir in Hepatitis B that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05453435Sun Yat-sen UniversityEntecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) | 2026-12 |
| NCT07816094Bangladesh Medical UniversityComparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver | 2027-01-19 |
| NCT07189377University Health Network, TorontoCombined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 37 studies testing entecavir in Hepatitis B, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 12 in Hepatitis B:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to develop observational clinical experience with the use of entecavir in participants who are either of Black/African-American race or of Hispanic ethnicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Entecavir
Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
Also known as: Baraclude, BMS-200475
Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48
HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately \<300 copies/mL.
Time frame: Week 48 of ETV treatment
Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48
HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection.
Time frame: Week 48
Percentage of Participants With HBV DNA by PCR Category at Week 48
HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay.
Time frame: Week 48
Percentage of Participants With Virologic Rebound Through Week 48 While on Continued Dosing With ETV
Virologic rebound is defined as a confirmed increase of ≥ 1 log10 in HBV DNA from the participant's nadir value (2 sequential HBV DNA measurements or last on-treatment measurement)
Time frame: through Week 48
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48
ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.
Time frame: Week 48
Percentage of Participants With Confirmed HBeAg Loss at Week 48 (for HBeAg-positive Participants Only)
HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week
Time frame: Week 48
Percentage of Participants With HBeAg Seroconversion at Week 48 (for HBeAg-positive Participants Only)
HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).
Time frame: Week 48
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
HBsAg = a part of the hepatitis B virus that, when in the blood, is a marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.
Time frame: Week 48
Percentage of Participants With HBsAg Seroconversion at Week 48
HBsAg = a part of the hepatitis B virus that, when in the blood, is a of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.
Time frame: Week 48
Mean log10 Reduction From Baseline in HBV DNA at Week 48
HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan AmpliPrep assay. Reduction in log10 HBV count=reduced viral load.
Time frame: baseline, Week 48
Percentage of Participants With HBV DNA < Other IU Cut-off Points That May be Clinically Relevant at the Time of Data Analysis
Time frame: Week 48
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to Adverse Events
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded.
Time frame: From enrollment through Week 52 + 5 days
Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF): Hematology
Criteria for hematology abnormalities were graded using the modified WHO grading system. Hemoglobin: \<=11.0 g/dL; White Blood Cells: \<4000/mm\^3; Absolute Neutrophils (includes absolute bands): \<1500/mm\^3; Platelets: \<=99,000/mm\^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.
Time frame: OT: From start of study therapy through Week 52 + 5 days; OF= End of OT period + 24-week follow-up
Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) : Serum Chemistry
The modified World Health Oranization(WHO)grading system was used to grade the abnormalities. ULN=upper limit of normal. Alanine aminotransferase:\>1.25xULN, Aspartate aminotransferase:\>1.25xULN, Alkaline Phosphatase:\>1.25xULN, Total Bilirubin:\>1.1xULN, Serum Lipase:\>1.10xULN, Creatinine:\>1.1xULN, Blood Urea Nitrogen:1.25xULN, Hyperglycemia:\>116 mg/dL, Hypoglycemia:\<64 mg/dL, Hyponatremia:\<132meq/L, Hypokalemia:\<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, \<3 g/dL; Hypernatremia:\>148 meq/L, Hyperkalemia:\>5.6 meq/L, Hypokalemia:\<3.4 meq/L, Hyperchloremia:\>113 meq/L, Hypochloremia:\<93 meq/L
Time frame: OT: From start of study therapy through Week 52 + 5 days; OF= End of OT period + 24-week follow-up
A total of 131 participants were enrolled at 27 sites.
| Milestone | Black/ African American | Hispanic |
|---|---|---|
| Started | 40 | 6 |
| Discontinued prior to week 48 visit | 1 | 1 |
| Discontinued at or after week 48 visit | 2 | 1 |
| Completed | 37 | 4 |
| Not completed | 3 | 2 |
| Withdrew: Lost to follow-up | 3 | 2 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. LOQ is the level above which quantitative results may be obtained with a specified degree of confidence. The LOQ is mathematically defined as equal to 10 times the standard deviation of the results for a series of replicates used to determine a justifiable limit of detection.
| percentage of participants | Black / African American | Total |
|---|---|---|
| Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48 | 12.5 (NA to NA) | 13.0 (3.3 to 22.8) |
HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay.
| percentage of participants | Black / African American | Total |
|---|---|---|
| <50 IU/mL (< 300 copies/mL) | 72.5 | 69.6 |
| 50 to <172 IU/mL (300 to < 103 copies/mL) | 0 | 0 |
| 172 to <1720 IU/mL (103 to < 104 copies/mL) | 10.0 | 10.9 |
| 1720 to <17200 IU/mL (104 to < 105 copies/mL) | 5.0 | 4.3 |
| ≥17,200 IU/mL (≥105 copies/mL) | 0 | 0 |
| Missing | 12.5 | 15.2 |
Virologic rebound is defined as a confirmed increase of ≥ 1 log10 in HBV DNA from the participant's nadir value (2 sequential HBV DNA measurements or last on-treatment measurement)
| percentage of participants | Black / African American | Total |
|---|---|---|
| Percentage of Participants With Virologic Rebound Through Week 48 While on Continued Dosing With ETV | 0 | 0 |
ALT normalization=ALT level being less than or equal to 1 times the upper limit of normal (ULN). ULN for ALT is 37 U/L.
| percentage of participants | Black / African American | Total |
|---|---|---|
| Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48 | 67.5 | 67.4 |
HBeAg is a hepatitis B viral protein. HBeAg loss = HBeAg-negative at the specified analysis week
| percentage of participants | Black / African American | Total |
|---|---|---|
| Percentage of Participants With Confirmed HBeAg Loss at Week 48 (for HBeAg-positive Participants Only) | 50.0 | 53.8 |
HBeAg is a hepatitis B viral protein. HBeAg Seroconversion = HBeAg Loss and Presence of Hepatitis B e Antibody (HBeAb).
| percentage of participants | Black / African American | Total |
|---|---|---|
| Percentage of Participants With HBeAg Seroconversion at Week 48 (for HBeAg-positive Participants Only) | 40.9 | 46.2 |
HBsAg = a part of the hepatitis B virus that, when in the blood, is a marker of infection. HBsAg loss = HBsAg-negative at the specified analysis week.
| percentage of participants | Black / African American | Total |
|---|---|---|
| Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48 | 5.0 | 6.5 |
HBsAg = a part of the hepatitis B virus that, when in the blood, is a of infection. HBs seroconversion is defined as HBsAg loss with positive HBsAb.
| percentage of participants | Black / African American | Total |
|---|---|---|
| Percentage of Participants With HBsAg Seroconversion at Week 48 | 2.5 | 4.3 |
HBV DNA was analyzed by PCR, using the Roche COBAS®TaqMan TaqMan AmpliPrep assay. Reduction in log10 HBV count=reduced viral load.
| log10 IU/mL | Black / African American | Total |
|---|---|---|
| Baseline | 7.1 ± 0.26 | 7.0 ± 0.25 |
| HBV DNA at Week 48 | 1.88 ± 0.100 | 1.87 ± 0.091 |
| Change from baseline | -5.22 ± 0.249 | -5.18 ± 0.231 |
No measurements were reported for this outcome.
AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was an overdose. Participants who discontinued the study due to any AEs were recorded.
| participants | Black / African American | Hispanic | Total |
|---|---|---|---|
| Deaths | 0 | 0 | 0 |
| SAEs | 3 | 1 | 4 |
| Discontinuations Due to AEs | 0 | 0 | 0 |
| Any AE | 33 | 5 | 38 |
| Grade 3 - 4 AEs | 5 | 1 | 6 |
| Related AEs | 16 | 0 | 16 |
| Grade 2 - 4 Related AEs | 5 | 0 | 5 |
Criteria for hematology abnormalities were graded using the modified WHO grading system. Hemoglobin: \<=11.0 g/dL; White Blood Cells: \<4000/mm\^3; Absolute Neutrophils (includes absolute bands): \<1500/mm\^3; Platelets: \<=99,000/mm\^3; International Normalized Ratio: ≥ 1.5 and ≥ 0.5 from baseline.
| participants | Black / African American | Total |
|---|---|---|
| Hemoglobin-OT | 1 | 2 |
| Hemoglobin-OF; n=26 , 29 | 0 | 0 |
| White Blood Cells-OT | 15 | 18 |
| White Blood Cells-OF; n=26 , 29 | 7 | 8 |
| Neutrophils -OT | 13 | 13 |
| Neutrophils-OF; n=26 , 26 | 4 | 4 |
| Platelets-OT | 4 | 4 |
| Platelets-OF; n=26 , 29 | 0 | 0 |
| International Normalized Ratio-OT | 18 | 23 |
| International Normalized Ratio-OF; n=26 , 29 | 4 | 4 |
HBV DNA assessments were performed using the Roche COBAS® TaqMan AmpliPrep assay. HBV DNA \< 50 IU/mL = approximately \<300 copies/mL.
| percentage of participants | Black / African American | Total |
|---|---|---|
| Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48 | 72.5 (NA to NA) | 69.6 (56.3 to 82.9) |
The modified World Health Oranization(WHO)grading system was used to grade the abnormalities. ULN=upper limit of normal. Alanine aminotransferase:\>1.25xULN, Aspartate aminotransferase:\>1.25xULN, Alkaline Phosphatase:\>1.25xULN, Total Bilirubin:\>1.1xULN, Serum Lipase:\>1.10xULN, Creatinine:\>1.1xULN, Blood Urea Nitrogen:1.25xULN, Hyperglycemia:\>116 mg/dL, Hypoglycemia:\<64 mg/dL, Hyponatremia:\<132meq/L, Hypokalemia:\<3.4 meq/L, Albumin:≥1g/dL decrease from baseline, \<3 g/dL; Hypernatremia:\>148 meq/L, Hyperkalemia:\>5.6 meq/L, Hypokalemia:\<3.4 meq/L, Hyperchloremia:\>113 meq/L, Hypochloremia:\<93 meq/L
| participants | Black / African American | Total |
|---|---|---|
| Alanine aminotransferase-OT | 37 | 43 |
| Alanine aminotransferase-OF; n=26 , 29 | 3 | 4 |
| Aspartate aminotransferase-OT | 33 | 38 |
| Aspartate aminotransferase-OF; n=26 , 29 | 2 | 3 |
| Alkaline Phosphatase-OT | 3 | 3 |
| Alkaline Phosphatase-OF; n=26 , 29 | 1 | 1 |
| Albumin-OT | 3 | 5 |
| Albumin-OF; n=26 , 29 | 0 | 0 |
| Total Bilirubin-OT | 7 | 7 |
| Total Bilirubin-OF; n=26 , 29 | 3 | 4 |
| Serum Lipase-OT | 12 | 14 |
| Serum Lipase-OF; n=26 , 29 | 1 | 1 |
| Creatinine-OT | 3 | 3 |
| Creatinine-OF; n=26 , 29 | 0 | 0 |
| Blood Urea Nitrogen-OT | 2 | 2 |
| Blood Urea Nitrogen-OF; n=26 , 29 | 0 | 0 |
| Hyperglycemia-OT | 14 | 15 |
| Hyperglycemia-OF; n=26 , 29 | 5 | 5 |
| Hypoglycemia-OT | 5 | 5 |
| Hypoglycemia-OF; n=26 , 29 | 1 | 1 |
| Hypernatremia-OT | 0 | 0 |
| Hypernatremia-OF; n=26 , 29 | 0 | 0 |
| Hyponatremia-OT | 3 | 3 |
| Hyponatremia-OF; n=26 , 29 | 0 | 1 |
| Hyperkalemia-OT | 0 | 0 |
| Hyperkalemia-OF; n=26 , 29 | 0 | 0 |
| Hypokalemia-OT | 3 | 3 |
| Hypokalemia-OF; n=26 , 29 | 0 | 0 |
| Hyperchloremia-OT | 0 | 0 |
| Hyperchloremia-OF; n=26 , 29 | 0 | 0 |
| Hypochloremia-OT | 0 | 0 |
| Hypochloremia-OF; n=26 , 29 | 0 | 0 |
Collected over 52 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entecavir (ETV) | — | 4/46 (8.7%) | 21/46 (45.7%) |
| Event | Entecavir (ETV) |
|---|---|
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/46 |
| RENAL CELL CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/46 |
| PYREXIAGeneral disorders | 1/46 |
| ANGINA PECTORISCardiac disorders | 1/46 |
| ASCITESGastrointestinal disorders | 1/46 |
| BLOOD GLUCOSE ABNORMALInvestigations | 1/46 |
| HEADACHENervous system disorders | 1/46 |
| LEUKOCYTOSISBlood and lymphatic system disorders | 1/46 |
| LOBAR PNEUMONIAInfections and infestations | 1/46 |
| PNEUMONIAInfections and infestations | 1/46 |
| Event | Entecavir (ETV) |
|---|---|
| HEADACHENervous system disorders | 8/46 |
| ABDOMINAL PAINGastrointestinal disorders | 6/46 |
| DIARRHOEAGastrointestinal disorders | 5/46 |
| PYREXIAGeneral disorders | 4/46 |
| BACK PAINMusculoskeletal and connective tissue disorders | 4/46 |
| FATIGUEGeneral disorders | 4/46 |
| INFLUENZAInfections and infestations | 4/46 |
| NAUSEAGastrointestinal disorders | 4/46 |
| SOMNOLENCENervous system disorders | 3/46 |
| URINARY TRACT INFECTIONInfections and infestations | 3/46 |
| Age Continuous(years) | Black/ African American | Hispanic | Total |
|---|---|---|---|
| Median | 39.0 (22 to 67) | 48.0 (29 to 69) | 40.0 (22 to 69) |
| Sex: Female, Male(Participants) | Black/ African American | Hispanic | Total |
|---|---|---|---|
| Female | 9 | 2 | 11 |
| Male | 31 | 4 | 35 |
| Race/Ethnicity, Customized(participants) | Black/ African American | Hispanic | Total |
|---|---|---|---|
| Hispanic / Latino | 0 | 6 | 6 |
| Not Hispanic / Latino | 18 | 0 | 18 |
| Missing | 22 | 0 | 22 |
| Race/Ethnicity, Customized(participants) | Black/ African American | Hispanic | Total |
|---|---|---|---|
| Black/ African American | 40 | 0 | 40 |
| White | 0 | 6 | 6 |
| Region of Enrollment(participants) | Black/ African American | Hispanic | Total |
|---|---|---|---|
| Brazil | 21 | 0 | 21 |
| Mexico | 0 | 2 | 2 |
| South Africa | 3 | 0 | 3 |
| United States | 16 | 4 | 20 |
| Hepatitis B surface antigen (HBsAg) status at baseline(participants) | Black/ African American | Hispanic | Total |
|---|---|---|---|
| Positive | 40 | 4 | 44 |
| Negative | 0 | 0 | 0 |
| Missing | 0 | 2 | 2 |
| Hepatitis B e antigen (HBeAg) status at baseline(participants) | Black/ African American | Hispanic | Total |
|---|---|---|---|
| Positive | 22 | 4 | 26 |
| Negative | 18 | 2 | 20 |
| Hepatitis B e antibody (HBeAb) at baseline(participants) | Black/ African American | Hispanic | Total |
|---|---|---|---|
| Positive | 19 | 2 | 21 |
| Negative | 21 | 4 | 25 |
3 further baseline measures are reported on the registry.
The record gives a start of Nov 2006, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir